9TH ANNUAL DPHARM

DISRUPTIVE INNOVATIONS TO ADVANCE CLINICAL TRIALS

September 17-18, 2019

Renaissance Boston Waterfront Hotel, BOSTON, MA

EXECUTIVE SPONSORS

ERT Confidence at every turn

IMS Health & Quintiles are now IQVIA

ORACLE Health Sciences

parexel

PRAHEALTHSCIENCES

pwc

Trialspark

Organized by the Conference Forum | www.theconferenceforum.org | #DPharm2019

DAY ONE - TUESDAY, SEPTEMBER 17, 2019

7:45 am
Registration & Coffee/Tea hosted by MMG

Patient Advocate Keynote

8:30 am
Patient Advocate Opening Presentation
Fewer than 1% of the women who audition for the famed Radio City Rockettes make the roster and ironically, fewer than 5% of women under 40 get breast cancer. Our patient advocate keynote, Alyssa Epstein has experienced both. This veteran professional dancer will share her patient story, what mattered to her most as a patient and what it took to get back on stage.
Alyssa Epstein
Patient Advocate, Radio City Rockette and Inspiration

9:00 am
Co-Chairs' Opening
Tammy Guld
Janssen Clinical Innovation Global Lead, **Janssen**

Keynote

9:05 am
Keynote: Modernizing Clinical Trials, Frameworks and Priorities
Scott Gottlieb, MD
23rd Commissioner of the FDA

9:45 am
Leadership & Innovation Keynote TBA

10:05 am
Grand Opening of the DPharm Networking & Exhibits Café
- Breakfast
- Partnering Tables
- Meet the exhibitors
- Networking

Disruptive Restoration Cornerstone Speaker

10:45 am
Good, Better…Balancing Innovation with Solid Common Sense to Deliver Innovative Medicines
Merck is walking the walk in disrupting how to restore best practices for people, product and productivity. With a clear vision on output, their remarkable team mapped a plan to an enterprise to change operational delivery. In this R&D Leadership session hear the story on how they are delivering what they promise:
- How to plan upfront once and do it properly
- Getting the basics right and what do you need to disrupt to get there
- Significant changes on greatly improving monitoring
- The use of iPad technology to monetize CRA visits
- How monitoring reports got reduced from 8 to 2
- Building a stable workforce with strong employee engagement
- Behavior, structure, systems and tools
- Scaling it

Mark Travers, PhD, MBA
VP, Head of GCTO Regions, Monitoring Excellence, Global Operations, **Merck & Co**

11:10 am
Actions to Embrace and Support Innovation for the Benefit of Patients
Shwen Gwee, PhD
Co- Founder, Novartis Biome, and General Manager, Head of Open Innovation, **Novartis**

Guest Keynote

11:20 am
The World's 50 Most Innovative Companies 2019
Fast Company magazine publishes an annual innovation report ranking businesses making the most profound impact on both industry and culture demonstrating a range of ways to succeed in a competitive world. In particular, they rank the top 50 companies and we are delighted to welcome the Deputy Editor of Fast Company to tell us about:
- Defining Innovation
- The process for selecting companies as the World's 50 Most Innovative
- Interesting examples of Fast Companies top 50 most innovative companies
- Common elements in the identified 50 companies? Any major themes?
- Thoughts based on the top 50 list over the years on what the key enablers are of sustaining innovation over a longer period of time
- Established companies that have either re-invented themselves or surprised Fast Company with something innovative for their customers
- Favorites to highlight and biggest surprises
- Thoughts on which companies can change the world and why
- Advice for pharma R&D developers

David Lidsky, JD
Deputy Editor, **Fast Company**
with
Shwen Gwee, PhD
Co- Founder, Novartis Biome, and General Manager, Head of Open Innovation, **Novartis**

Innovative Sources and Solutions

We have seen a really nice evolution in companies that are enabling many new capabilities that can radically improve and disrupt the future of clinical trials and the patient experience. The companies listed below have been invited to present on what they are specifically solving to advance clinical trials, increase efficiencies and reduce the burden to patients and investigators.
Attendees are free to choose among the following presenting companies:

11:45 am	**Track A** **Innovative Digital Solutions** Moderator: **Nikhil Kavimandan, PhD** *Director of Innovation & Strategy, Global Development Operations,* **Novartis**	**Track B** **Innovative Patient Solutions** Moderator: **Sandra Freeman** *Associate Director, Global Clinical Operations,* **Johnson and Johnson**	**Track C** **Where Are They Now?** Moderator: **Ülo Palm, MD, PhD** *SVP, Head, Global Drug Development Operations,* **Allergan**
	Oracle	PA Consulting	Elligo
	Clinical Ink	BBK	MRN
	4G	ClinEdge	Edetek
	Snaplot	Greenphire	GlobalCare Clinical Trials
	Complion	Clincierge	Quest Diagnostics
			Protocol First/Clinical Pipe
12:50 pm	**Lunch & Networking**		

Pharma Innovation 2019 Reporting from the Trenches

This is a great opportunity to hear from several different pharma companies reporting on a specific example of innovation applied to advance clinical trials within the last 12 months. Each session addresses the milestones, challenges and problems with adoption.
Attendees are free to choose among the following presenting companies:

2:00 pm	**Track A** Moderator: **Tammy Guld** *Janssen Clinical Innovation Global Lead,* **Janssen**	**Track B** Moderator: **Joseph Kim, MBA** *Sr Advisor, Clinical Operations and Digital Registry, Digital Health Office Translational Technology & Innovation,* **Eli Lilly**	**Track C** Moderator: **Paulo Moreira** *Global Head of Clinical Operations,* **Agenus**
	Janssen	Genentech	Bayer
	Sanofi	Pfizer	Celgene
	Novartis	Allergan	Eli Lilly
		Eli Lilly	Takeda
3:30 pm	**Afternoon Break in the DPharm Networking & Exhibits Café hosted by:** COVANCE SOLUTIONS MADE REAL® • Refreshments including chocolates by Boston's oldest chocolatier and ice cream. • Partnering Tables • Meet the Exhibitors • Networking		

Zeitgeist Talk Choices

4:00 pm	**Choice A** **23andMe and the Future of Clinical Trials** **Shawn Tedman, MBA** *Director, Clinical Trials Business,* **23andMe** with **Ken Getz, MBA** *Director of Sponsored Research*, **Tufts CSDD** and *Founder*, **CISCRP**	**Choice B** **Voice Technology for Clinical Trials** Led by: **Shwen Gwee, PhD** *Co- Founder, Novartis Biome, and General Manager, Head of Open Innovation,* **Novartis**

4:30 pm

DPharm Idol 2019

Now in its 8th year, DPharm Idol is a live show featuring a select group of innovators who present what they believe is a disruptive technology or service that could be a changing force for clinical trials. Each of the pre-approved presenting companies gives a quick-fire session followed by questions from the DPharm Idol judges. The questions from the judges provide great examples of how to assess technologies/services for their disruptive quality, especially for the benefit of patients. Past DPharm Idol winners include Medidata, Spaulding Clinical, ePharma Solutions, Science 37, Florence Healthcare, PhysIQ and Medable.
Who will be the DPharm Idol 2019 winner?

Presenting Companies as of June 10:

Trialscout
Irfan Khan, MD, *CEO*

x-Cures
Mika Newton, *CEO*

Shimmer Research
Geoff Gill, *President*

Intelligencia
Vangelis Vergetis, PhD, *Co-Founder*

Trials.ai
Kim Walpole, *Founder and CEO*

Opening Presentation with DPharm Idol 2018 Winner: Medable

DPharm Idol MC:
Valerie Bowling
Executive Director, **DPharm**

DPharm Idol Judges:
Esther Dyson
Executive Founder, **Way to Wellville**

Sandra Freeman
Associate Director, Global Clinical Operations, **Johnson and Johnson**

Cindy Geoghegan
Cancer Veteran and Patient Advocate

Hassan Kadhim
Director, Head of Clinical Trial Business Capabilities, **BMS**

Ülo Palm, MD, PhD
SVP, Head, Global Drug Development Operations, **Allergan**

Chandra Ramanathan, PhD, MBA
Head, East Coast Innovation Center, **Bayer, US**

Jessica Scott, MD, JD
Head of R&D Patient Engagement, **Takeda**

John Varaklis
Head of Global Clinical Operations, **Roche Pharmaceutical Research and Early Development (pRED)**

5:45 pm
DPharm Annual Networking Reception & Partnering

DAY TWO - WEDNESDAY, SEPTEMBER 18, 2019

8:00 am

DPharm Café Opens

- Breakfast
- Partnering Tables
- Meet the exhibitors
- Networking

8:30 am

Co-Chairs' Opening & DPharm Idol Winner Announcement

Tammy Guld
Janssen Clinical Innovation Global Lead, **Janssen**

Zeitgeist Speaker on Big Data & AI for Drug Development

8:40 am

The Collective Struggle to Evolve a Drug Development Organization's Data and Analytics Culture and Capabilities

Perhaps one of the most inquisitive CDOs in R&D, Milind Kamkolkar joins DPharm for the first time to address:

- The theory of going digital in drug development?
- Identifying hype from reality
- What is the problem we are trying to solve?
- Taking a big, complex organization and evolving it to be digitally modern
- Given the distance between data and decision making, how can we accelerate this from R&D to commercial?
- What is the intended use of the data?
- The social and ethical use of the data
- Priorities, structure, culture and next steps

Milind Kamkolkar
Chief Data Officer, **Cellarity**

Healthgrades Keynote

9:05 am

Healthgrades Founder Kerry Hicks on Transparency and the Future of Patient Expectations

"Everyone likes progress and no one likes change." **Kerry Hicks**

Kerry Hicks is the founder of Healthgrades, which put the power of transparency into millions of patients' hands on provider visit experiences. In this fireside chat, we will begin with his vision for Healthgrades, what it was like to build it, early fears, and unintended consequences. We will discuss Kerry's three top principals: 1. Transparency 2. Accountability and 3. Empowerment. Our conversation will also cover the intersection between patient experience, technology and clinical research. Finally, we will get Kerry's insights on why you must consider transparency with everything you build going forward, the customer/patient experience, key changes in clinical research and who may come along to disrupt us.

Kerry Hicks, MBA
Founder, **Healthgrades**
with
Craig Lipset, MBA
Former Head of Clinical Innovation, **Pfizer**

Guest Design Speaker

9:25 am

Starbucks: Innovation for the End User Experience

Starbuck's guest speaker, Robert Mercer sits down with Eli Lilly's Joe Kim to discuss an-out-of industry example from one of the best companies to cherish the end user experience. We will find out the innovation priorities at Starbucks and in particular how they designed their mobile experience with the customer in mind. More specifically:

- Barriers and executive buy-in
- Rolling out the mobile experience
- Balancing the scale of new solutions across stores around the globe with the need to maintain existing operations and delivery
- How Starbucks engages with customers to learn and develop innovative new solutions

Robert Mercer
Design Director, Global Digital Products, **Starbucks**
with
Joseph Kim, MBA
Sr Advisor, Clinical Operations and Digital Registry, Digital Health Office, Translational Technology & Innovation, **Eli Lilly**

9:45 am

Today Show @DPharm

Host:
Michelle Shogren
Director of Innovation, Pharma R&D Clinical Operations, **Bayer**

Guest Companies:

IQVIA

PAREXEL

ERT

10:30 am

Morning Networking in the DPharm Café

- Refreshments
- Partnering Tables
- Meet the exhibitors
- Networking

Hot Topic Break Out Choices

	Section A: Hot Topic #1	Section B: Hot Topic #1
11:10 am	**Operationalizing EHR eSource – Ruthless Separation of Hype from Reality** DPharm welcomes one of the most credible voices in e-source, Dr Meredith Zozus for the first time to this event. Dr Zozus will begin briefly with why e-source can be truly disruptive to clinical studies from overall cost reduction, the ability to cut down on clinical data monitoring, reducing errors on data collection, site burden to the enormous decrease in manual labor. Joining DPharm for the first time as well is Pfizer's Michele Cherry who is working with Dr Zozus on operationalizing esource at Pfizer. Together, they will show the DPharm audience how esource works and talk about what is required to implement it on a multicenter clinical study. Expect ruthless separation of hype from reality and discussion around the following questions: • What makes a study a good or bad candidate for EHR esource and why? • How much of the data is really available in the EHR? • How does operationalizing esource change site selection and start up time-lines? • How to reengineer start up times around esource? • How to make ends meet from a regulatory perspective to operational perspective? • What are the unknowns and pitfalls? • Is the technology ready? Are the sites ready? Is my organization ready? • How to prompt discussions in your organization about when to jump on the adoption curve? • How do we gain experience with EHR esource and de-risk it for my company? **Meredith Zozus, PhD** *Associate Professor and Vice Chair for Academic Programs,* **University of Arkansas for Medical Sciences' College of Medicine—Department of Biomedical Informatics** with **Michele Cherry** *Senior Manager, Client Partner,* **Pfizer**	**Master Protocols are the Future of Clinical Research: Patient-Centric R&D and Transformational Efficiencies** We know patients, regulators, investigators and drug developers have a common interest in bringing safe and effective therapies quickly to patients needing them, yet the familiar clinical trial process contains built-in inefficiencies leading to delays, redundancies, and escalating costs. Master Protocols enable drug developers to answer questions more quickly, and patients participating in clinical trials to have the best opportunity to access promising therapies while contributing to the scientific understanding of their condition thereby allowing the field to progress as rapidly as possible. In this collaborative session representing both the patient and drug developer perspectives, learn what it takes to make MAPs a reality – the opportunities, challenges, why it's disruptive and how all stakeholders can contribute. **Abby Bronson** *SVP of Research Strategy,* **Parent Project Muscular Dystrophy** **Daniel Millar, MBA** *Senior Director, Strategic Business Transformation Quantitative Sciences,* **Janssen Research & Development**

	Hot Topic Break Out Choices		Two Track Choices on Big Data/AI and Patient-Centered Trials
	Section A: Hot Topic #2	**Section B: Hot Topic #2**	**Track A: Big Data Management & AI: How One will Lead to the Other, What to Expect and How to Prepare** When it comes to data science, we are all in the same boat and are trying to evolve together. The data science field is exploding with advancing technologies and algorithms. There is no AI without an understanding of big data management. We want AI to support data-driven decisions, but we need good data and to know what to assemble to truly be a data driven organization. What are the gaps for transformation in an environment with scarce data science talent?
11:35 am	**Hacking and Why it is Important for your Clinical Trials: Tales from the Biohacking Village @Defcon** Biohacking Village founder Janine Medina will cover a topic that we don't always think about, but when you get exposed to it, you're so glad as it makes you think deeper about clinical trial innovation, safety and privacy for patients, especially in this digital era. Janine is joined by former entrepreneur-in-residence at the FDA, Andrea Coravos where they discuss: • What is hacking? And why is it important for your clinical trial? • White Hat vs Black Hat • Security Bill of Materials for Connected Medical Devices / Wearables • Digital tools in trials and their vulnerabilities • Conventional trials and their vulnerabilities • What unexpected things can we learn from hackers when they look at the existing clinical trial process (the less scary things) • Coordinated disclosure • FDA's CyberMed Safety (Expert) Analysis Board (CYMSAB) • #WeHeartHackers, and FDA-led initiative around cybersecurity research • BHV at DEF CON **Janine Medina** *Executive Director*, **Biohacking Village** with **Andy Coravos** *CEO and Co-Founder*, **Elektra Labs**	**Case Study: The ADAPTABLE Trial and Shared Learnings from this Virtual Trial** The ADAPTABLE trial is the largest virtual trial ever run on the Medidata platform. Learn about the rationale around the decision to run the trial as a virtual trial, the impact on patient enrollment, engagement and retention as well as the incorporation of patients to inform the design of the trial and the tools used in the conduct of the study. **Michael Tucker** *Senior Product Solutions Specialist, Mobile Health,* **Medidata** with **Duke Clinical Research**	**Is Digital Science, Big Data, Machine Learning, and AI Going to Revolutionize Medical Research and Practice? Implications for Pharmaceutical R&D** • What is behind the terms "Digital Science, Big Data, Machine Learning, AI"? • Examples where these new technologies are shifting paradigms in medicine • What are the implications for pharmaceutical R&D? Can we sit it out or do we rapidly need to change? • What can AI do in development and what do we want AI to do in development? • How to separate hype from real opportunities to create value? • Why can't we successfully implement Digital Science without a Digital Culture? What is a Digital Culture? • How is Allergan creating a Digital Culture to drive the success of Digital Science **Ülo Palm, MD, PhD** *SVP, Head, Global Drug Development Operations,* **Allergan**

	Hot Topic Break Out Choices	
	Section B: Hot Topic #3	
11:50 am	**CTTI Update on RWD for Study Planning** Speaker TBA	
	Two Track Choices on Big Data/AI and Patient-Centered Trials	
	Track A: Big Data Management & AI: How One will Lead to the Other, What to Expect and How to Prepare When it comes to data science, we are all in the same boat and are trying to evolve together. The data science field is exploding with advancing technologies and algorithms. There is no AI without an understanding of big data management. We want AI to support data-driven decisions, but we need good data and to know what to assemble to truly be a data driven organization. What are the gaps for transformation in an environment with scarce data science talent?	**Track B: Getting Closer to Patient-Centered Trials** As an industry, we are on the road towards patient-centered trials. At DPharm, we report on industry shared learnings throughout the event and in this section, you will hear about milestones and actions for direct-to-patient trials, the formation of clinical trial communications between patients and investigators and about TransCelerate's P-PET.
12:00 pm		**Direct-to-Patient Clinical Trials Next Milestones and Actions to Get There** We have called direct-to-patient trials, virtual trials, flexible trials, siteless trials, remote trials, decentralized trials and more. Many of us have done pieces of these types of trials, but as an industry, this is still not the norm by a long shot. In this discussion, we report on our progress, identify what's missing to close the gaps and next steps and call to actions. Led by: **Craig Lipset, MBA** *Former Head of Clinical Innovation*, **Pfizer** with **Jacob LaPorte, PhD** *Global Head of Digital Development*, **Novartis** **Jules Mitchel, PhD** *President,* **Target Health**
12:05 pm	**AI Guest Speakers** **Karim Galil, MD** *CEO*, **Mendel.ai** with **Matthew Michela, MBA**, *President and CEO, Life Image,* **Mendel.ai**	
12:15 pm	**Chris Economos, MBA** *Chief Commercial Officer,* **PhysIQ** with	
12:20 pm	**Matt Pipke** *CTO,* **PhysIQ**	**Enhancing Clinical Trial Communications between Patients and Investigators** As an industry, we must prioritize building rapport with the patients who have instilled their trust and made a commitment to help researchers learn more about a disease and improve healthcare in the future. It's equally important for healthcare professionals to feel that they have the support they need to build strong relationships with patients in the clinical trial setting. The more clinical trial sponsors do to show empathy and personalize the interaction with patients, healthcare professionals and site staff, the better trials will be. This presentation is a call to action for the audience to invest in high quality conversations between site staff and patients/ study participants. • Understanding patient interest and motivation • Deepening the connection between patients and site staff • Empowering Patients The goal is for patients to feel more engaged with the trial, and to equip site staff with tools to drive patient-centered conversations. **Suzann Johnson** *Associate Director Investigator Patient Engagement, CIE*, **Janssen**
12:30 pm	**Managing Site and Study Performance in Clinical Trials with AI** with **Saama**	

<table>
<tr><th></th><th colspan="2">Two Track Choices on Big Data/AI and Patient-Centered Trials</th></tr>
<tr><td></td><td>Track A: Big Data Management & AI: How One will Lead to the Other, What to Expect and How to Prepare
When it comes to data science, we are all in the same boat and are trying to evolve together.
The data science field is exploding with advancing technologies and algorithms. There is no AI without an understanding of big data management. We want AI to support data-driven decisions, but we need good data and to know what to assemble to truly be a data driven organization. What are the gaps for transformation in an environment with scarce data science talent?</td><td>Track B: Getting Closer to Patient-Centered Trials
As an industry, we are on the road towards patient-centered trials. At DPharm, we report on industry shared learnings throughout the event and in this section, you will hear about milestones and actions for direct-to-patient trials, the formation of clinical trial communications between patients and investigators and about TransCelerate's P-PET.</td></tr>
<tr><td>12:40 pm</td><td></td><td>The Launch of the Patient Protocol Engagement Toolkit (P-PET)
The #1 way to make clinical trials patient-centric is to ask patients what they want.
We know that patients are empowered by knowledge of their diseases and understanding how drugs are developed and they want to take an active role in the drug development process. While sponsors recognize the importance of partnering with patients to create better experiences for clinical study participants, caregivers, and families, they do not always have the tools for engaging patients in study design and measuring patients' experiences during a clinical study.
For the first time attendees will preview the Patient Protocol Engagement Toolkit (P-PET). It entails a User and Resource Guide and templates that help teams consider necessary details when engaging patients during protocol development. Patient feedback during protocol development may help identify ways to improve patient experience and reduce patient burden.
The audience will also preview the recently made public Study Participant Feedback Questionnaire (SPFQ) toolkit. It includes the three questionnaires and a User Guide to help study teams consider necessary details to include the questionnaires into the study trial design. Collecting real-time feedback from clinical study patients may help identify burden/impact and inform the steps to take to make the current or future studies less burdensome to patients. These tools support innovation for the benefit of patients and drug development.
Michele Teufel
Feasibility and Recruitment Partner, AstraZeneca</td></tr>
<tr><td>12:45 pm</td><td>What Needs to be Assembled Among Teams and Infrastructure to Support AI Deployment?
• What to assemble to truly be a data driven organization?
• Adoption challenges
• Barriers
• Next steps to AI adoption
Milind Kamkolkar
Chief Data Officer, Cellarity
Ülo Palm, MD, PhD
SVP, Head, Global Drug Development Operations, Allergan</td><td></td></tr>
<tr><td>1:00 pm</td><td colspan="2">Lunch & Networking</td></tr>
<tr><td>2:00 pm - 2:30 pm</td><td colspan="2">RDL Leadership Keynote
KPIs that Support Innovation for Patient-Engagement
Dr Plump leads Takeda's global Research & Development organization, where he provides strategic direction and oversight. He specializes in bringing an unwavering focus on patients and a deep commitment to innovation and positive change in the healthcare industry. Dr Plump is joined by his colleague and DPharm veteran, Dr Jessica Scott in a fireside keynote to share the development of KPIs that support innovation for patient-engagement.
Andrew Plump, MD, PhD
Chief Medical and Scientific Officer, Takeda
with
Jessica Scott, MD, JD
Head of R&D Patient Engagement, Takeda</td></tr>
</table>

Super Session Choices

The concluding section at DPharm offers two compelling tracks addressing upskilling site staff where we are proudly partnering with ACRP and CRAACO, which focuses on the integration of research and care. Attendees are free to "pick and mix".

	Choice #1	Choice #2
	Workforce Innovation: Upskilling Site Staff for 21st C Clinical Trials Moderated by: **Jim Kremidas**, *Executive Director,* **ACRP** This section of DPharm addresses one of the elephants in the room. As an industry, we are not doing a good enough job consistently ensuring the skill levels and training of site staff. The results of this is so costly that not even Tufts CSDD have a number on it. In this section, we are going to address head on the source of this problem and where innovation fits in so we can: • Understand the inequality of the workforce performance in clinical trials at the site level • Establish a definition and alignment on the competencies required for clinical research staff • Establish industry standards for validating the qualifications of site staff • Define a career path for site staff to enhance retention and quality • Improve enrollment, accurate data, operational efficiencies and overall quality in the clinical research ecosystem This will get achieved through these sessions:	**CRAACO: Clinical Research as a Care Option** Five years ago, DPharm featured a session highlighting an example of research offered as a care option within a health system with positive health outcomes. The interest from both health systems and pharma in learning about the details of how to make this happen continues to grow. DPharm is committed to dedicating this section called CRAACO to highlight examples of bringing research closer to patients and patients closer to research.
2:35 pm	**We Have a Problem with Workforce Performance at the Site Level and Here is What We Can Do Now** **David Vulcano, MBA** *VP, Research Compliance & Integrity,* **HCA Healthcare**	**Understanding the Goals of Care vs Research** • Goals for care vs goals for research • Oversight and governance • Is there an ethical burden of breaking down the line between research and care? • What is the hesitation behind embracing the blurring of this boundary? • In areas like precision medicine, this is already blurring, how to manage? • Hurdles stopping large companies from thinking about this – Is it practical? Ethical? **Jennifer Byrne**, *CEO*, **Javara** **Jonathan Jackson, PhD**, *Director, CARE Research Center,* **Massachusetts General Hospital** **Sarah Larson**, *Director of Global Clinical Operations,* **Biogen**
2:50 pm		**Weighing Your Options in Considering Clinical Research from a Patient Perspective** Strategies and ideas to reduce the burden to patients Understanding of clinical care with their physician? Communication, consent and data sharing Led by: **Cindy Geoghegan**, *Cancer Veteran and Patient Advocate*
3:05 pm	**How to Develop Career Paths and Build the Competency of the Clinical Research Workforce/Individuals via Organizational Level Changes** **Dave Morin, MD** *Director of Research*, **Holston Medical Group**	
3:15 pm	**Denise Snyder, MS, RD, LDN** *Associate Dean for Clinical Research,* **Duke University School of Medicine** **Mark Travers, PhD, MBA** *VP, Head of GCTO Regions, Monitoring Excellence, Global Operations,* **Merck & Co**	**How Sanford Health Systems Integrated Clinical Care and Clinical Research – Going from 3% of Patients in Clinical Trials to 10% in 8 years: Case Study** • Creating a system for all providers to work seamlessly • Educational programs and continual training across all areas of care and specialties for trial offerings • Identifying gaps in trial availability • Attracting providers who are interested in clinical research for their patients • NCORP site **Jecinta Scott, MS, CCRP**, *Director, Clinical Research Oncology*, **Sanford Research**

Super Session Choices

The concluding section at DPharm offers two compelling tracks addressing upskilling site staff where we are proudly partnering with ACRP and CRAACO, which focuses on the integration of research and care. Attendees are free to "pick and mix".

	Choice #1	Choice #2
	Workforce Innovation: Upskilling Site Staff for 21st C Clinical Trials Moderated by: **Jim Kremidas**, *Executive Director,* **ACRP** This section of DPharm addresses one of the elephants in the room. As an industry, we are not doing a good enough job consistently ensuring the skill levels and training of site staff. The results of this is so costly that not even Tufts CSDD have a number on it. In this section, we are going to address head on the source of this problem and where innovation fits in so we can: • Understand the inequality of the workforce performance in clinical trials at the site level • Establish a definition and alignment on the competencies required for clinical research staff • Establish industry standards for validating the qualifications of site staff • Define a career path for site staff to enhance retention and quality • Improve enrollment, accurate data, operational efficiencies and overall quality in the clinical research ecosystem This will get achieved through these sessions:	**CRAACO: Clinical Research as a Care Option** Five years ago, DPharm featured a session highlighting an example of research offered as a care option within a health system with positive health outcomes. The interest from both health systems and pharma in learning about the details of how to make this happen continues to grow. DPharm is committed to dedicating this section called CRAACO to highlight examples of bringing research closer to patients and patients closer to research.
3:50 pm	**Collaborative Efforts for Workforce Efficiency and Productivity that are Disruptive** **Jennifer Byrne** *CEO*, **Javara** **Beth Harper** *Workforce Innovation Officer,* **ACRP**	
3:45 pm	**Denise Snyder, MS, RD, LDN** *Associate Dean for Clinical Research,* **Duke University School of Medicine**	**Pfizer's Collaborative Approach with a Healthcare System to Integrate Clinical Research into Clinical Care** **Munther Baara** *Head, New Clinical Paradigm,* **Pfizer**
4:10 pm		**The Need for an Internal Advocate: How Can Clinical Research Professionals bring CRAACO into Clinical Operations?** In this session, participants will receive an insider's view of how being an advocate within pharma for patients and sites can benefit clinical trial awareness, participation, and experiences. **Kelly McKee** *Head, Patient Recruitment, Rare Diseases,* **Vertex Pharmaceuticals**
4:30 pm	**DPharm Concludes**	